The type 2 diabetes gene product STARD10 is a phosphoinositide binding protein that controls insulin secretory granule biogenesis.
Fiche publication
Date publication
mai 2020
Journal
Molecular metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ALPY Fabien
Tous les auteurs :
Carrat GR, Haythorne E, Tomas A, Haataja L, Müller A, Arvan P, Piunti A, Cheng K, Huang M, Pullen TJ, Georgiadou E, Stylianides T, Amirruddin NS, Salem V, Distaso W, Cakebread A, Heesom KJ, Lewis PA, Hodson DJ, Briant LJ, Fung ACH, Sessions RB, Alpy F, Kong APS, Benke PI, Torta F, Keong Teo AK, Leclerc I, Solimena M, Wigley DB, Rutter GA
Lien Pubmed
Résumé
Risk alleles for type 2 diabetes at the STARD10 locus are associated with lowered STARD10 expression in the β-cell, impaired glucose-induced insulin secretion and decreased circulating proinsulin:insulin ratios. Although likely to serve as a mediator of intracellular lipid transfer, the identity of the transported lipids, and thus the pathways through which STARD10 regulates β-cell function, are not understood. The aim of this study was to identify the lipids transported and affected by STARD10 in the β-cell and and the role of the protein in controlling proinsulin processing and insulin granule biogenesis and maturation.
Mots clés
Type 2 diabetes, insulin granule biogenesis, lipid transporter, pancreatic β-cell, phosphoinositides
Référence
Mol Metab. 2020 May 13;:101015